Arcus Biosciences, Inc. (RCUS) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Arcus Biosciences is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for cancer and inflammatory/autoimmune diseases. The company operates as a single reportable segment and has not yet generated revenue from product sales, relying instead on collaboration and licensing agreements.
Key Financial Metrics
| Metric (in millions) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $17 | $28 |
| Net Loss | $(128) | $(112) |
| Net Loss Per Share (Basic & Diluted) | $(1.02) | $(1.14) |
| Research & Development Expenses | $122 | $122 |
| General & Administrative Expenses | $29 | $28 |
| Cash, Cash Equivalents & Marketable Securities | $876 | $1,010 (Dec 31, 2025) |
| Long-Term Debt | $100 | $99 |
| Net Cash Used in Operating Activities | $(138) | $(132) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 39% to $17 million, primarily driven by lower development services revenue from the Gilead Collaboration.
- Net Loss Increase: Net loss increased 14% to $128 million, though net loss per share improved due to share count increases.
- R&D Expense Stability: R&D expenses remained flat at $122 million. Late-stage development costs increased due to investment in casdatifan and the PRISM-1 study, offset by a wind-down of domvanalimab studies and a 57% decrease in early-stage development costs.
- Liquidity Position: Cash and marketable securities decreased by approximately $134 million from the prior quarter end, reflecting operating cash burn partially offset by net proceeds from marketable securities maturities.
Guidance, Outlook, and Material Events
- Clinical Discontinuations:
- STAR-121: Discontinued in April 2026 due to futility. This Phase 3 study evaluated domvanalimab plus zimberelimab in metastatic NSCLC.
- eVOLVE-RCC02: Enrollment was not re-opened in March 2026 following observations of potential immune-mediated adverse events.
- Gilead Collaboration Update: Gilead decided not to make the option continuation payment due on the sixth anniversary. Consequently, Gilead's option rights to additional early-stage programs will end on July 14, 2026. Gilead retains time-limited options on specific programs (AB801, AB598, AB102, and a TNF inhibitor).
- Liquidity Outlook: Management believes current cash and marketable securities ($876 million) are sufficient to fund planned operations until at least the second half of 2028.
- Debt Covenants: The company is subject to covenants under its Hercules Capital agreement, including minimum cash requirements beginning July 2027. Failure to meet these could trigger repayment obligations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $876 million cash balance against the projected burn rate, considering the wind-down of domvanalimab and continued investment in casdatifan.
- Gilead Option Expiry: Monitor the July 14, 2026 deadline for Gilead's option rights and the potential impact on future revenue streams from the collaboration.
- Clinical Pipeline Status: Assess the impact of the STAR-121 discontinuation on the overall TIGIT program strategy and the progress of the casdatifan (HIF-2α) program.
- Debt Covenants: Review the specific financial covenants in the Hercules Capital agreement, particularly the minimum cash covenant effective July 2027.
- Manufacturing Risks: Evaluate the reliance on WuXi Biologics (China) as the sole manufacturer for zimberelimab and domvanalimab in light of the U.S. BIOSECURE Act and geopolitical tensions.